Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara Galimberti

Showing results (1-10 of 313) with videos related to

Pageof 32
Sort By:
Current Treatment Options in Oncology|October 11, 2007
Hairy Cell LeukemiaRossella Riccioni, Sara Galimberti, Mario Petrini
Journal of Clinical Medicine|December 2, 2020
Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?Simona Soverini, Simona Bernardi, Sara Galimberti
Leukemia Research|October 19, 2006
Bortezomib inhibits T-cell function versus infective antigenic stimuli in a dose-dependent manner in vitroEnrico Orciuolo, Sara Galimberti, Mario Petrini
Haematologica|September 5, 2007
Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseasesDaniele Focosi, Sara Galimberti, Mario Petrini
Hematological Oncology|April 9, 2024
Novel monoclonal antibodies: A really specific therapy for light chain amyloidosisMaria Livia Del Giudice, Sara Galimberti, Gabriele Buda
Cancer Immunology, Immunotherapy : CII|November 4, 2023
Beyond BCMA, why GPRC5D could be the right way: treatment strategies with immunotherapy at relapse after anti-BCMA agentsMaria Livia Del Giudice, Sara Galimberti, Gabriele Buda
Leukemia Research|July 26, 2005
Imatinib therapy in Hypereosinophilic Syndrome: a case of molecular remissionGiulia Cervetti, Sara Galimberti, Giovanni Carulli, et al.
Journal of Leukocyte Biology|May 31, 2008
Conditioning response to granulocyte colony-stimulating factor via the dipeptidyl peptidase IV-adenosine deaminase complexDaniele Focosi, Richard Eric Kast, Sara Galimberti, et al.
Neuropharmacology|July 5, 2003
Dose-dependent induction of apoptosis by R-apomorphine in CHO-K1 cell line in cultureCarla Pardini, Francesca Vaglini, Sara Galimberti, et al.
Frontiers in Oncology|May 26, 2023
Editorial: Measurable residual disease in hematologic malignanciesFrancesco Buccisano, Raffaele Palmieri, Monica L Guzman, et al.
Pageof 32

Showing results (1-10 of 313) with videos related to

Sort By:
Pageof 32
Current Treatment Options in Oncology|October 11, 2007
Hairy Cell LeukemiaRossella Riccioni, Sara Galimberti, Mario Petrini
Journal of Clinical Medicine|December 2, 2020
Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?Simona Soverini, Simona Bernardi, Sara Galimberti
Leukemia Research|October 19, 2006
Bortezomib inhibits T-cell function versus infective antigenic stimuli in a dose-dependent manner in vitroEnrico Orciuolo, Sara Galimberti, Mario Petrini
Haematologica|September 5, 2007
Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseasesDaniele Focosi, Sara Galimberti, Mario Petrini
Hematological Oncology|April 9, 2024
Novel monoclonal antibodies: A really specific therapy for light chain amyloidosisMaria Livia Del Giudice, Sara Galimberti, Gabriele Buda
Cancer Immunology, Immunotherapy : CII|November 4, 2023
Beyond BCMA, why GPRC5D could be the right way: treatment strategies with immunotherapy at relapse after anti-BCMA agentsMaria Livia Del Giudice, Sara Galimberti, Gabriele Buda
Leukemia Research|July 26, 2005
Imatinib therapy in Hypereosinophilic Syndrome: a case of molecular remissionGiulia Cervetti, Sara Galimberti, Giovanni Carulli, et al.
Journal of Leukocyte Biology|May 31, 2008
Conditioning response to granulocyte colony-stimulating factor via the dipeptidyl peptidase IV-adenosine deaminase complexDaniele Focosi, Richard Eric Kast, Sara Galimberti, et al.
Neuropharmacology|July 5, 2003
Dose-dependent induction of apoptosis by R-apomorphine in CHO-K1 cell line in cultureCarla Pardini, Francesca Vaglini, Sara Galimberti, et al.
Frontiers in Oncology|May 26, 2023
Editorial: Measurable residual disease in hematologic malignanciesFrancesco Buccisano, Raffaele Palmieri, Monica L Guzman, et al.
Pageof 32